CYTOTEC Drug Patent Profile

Which patents cover Cytotec, and what generic alternatives are available?

Cytotec is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in CYTOTEC is misoprostol. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the misoprostol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cytotec

A generic version of CYTOTEC was approved as misoprostol by ANI PHARMS on July 10^th, 2002.

Summary for CYTOTEC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	106
Patent Applications:	6,777
Drug Prices:	Drug price information for CYTOTEC
What excipients (inactive ingredients) are in CYTOTEC?	CYTOTEC excipients list
DailyMed Link:	CYTOTEC at DailyMed

See drug prices for CYTOTEC

Recent Clinical Trials for CYTOTEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stanford University	Phase 3
Cairo University	N/A
University of Texas at Austin	Phase 4

See all CYTOTEC clinical trials

Pharmacology for CYTOTEC

Drug Class

Prostaglandin E1 Analog

US Patents and Regulatory Information for CYTOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-003	Sep 21, 1990	AB	RX	Yes	No
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988	AB	RX	Yes	Yes

Expired US Patents for CYTOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-003	Sep 21, 1990
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988
Pfizer	CYTOTEC	misoprostol	TABLET;ORAL	019268-001	Dec 27, 1988

International Patents for CYTOTEC

See the table below for patents covering CYTOTEC around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	7501391
African Intellectual Property Organization (OAPI)	4910
Germany	2513212
Sweden	420199	FORFARANDE FOR FRAMSTELLNING AV 16-OXIDERADE PROSTANSYRADERIVAT
Philippines	16276	16-OXYGENATED PROSTANOIC ACID DERIVATIVES AND PROCESS OF PREPARATION
Argentina	207355	UN PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DEL ACIDO 7-(-(4-HIDROXI-4-ALQUIL-1-ALQUENIL)CICLOPENTANO)-1-HEPTANOICO

Market Dynamics and Financial Trajectory for CYTOTEC (Misoprostol)

Last updated: January 8, 2026

Executive Summary

CYTOTEC (misoprostol) stands as a widely used pharmaceutical primarily for the prevention of gastric ulcers and as a critical component in obstetric and gynecological applications, including medical abortion and labor induction. This analysis explores its current market landscape, growth drivers, competitive environment, regulatory factors, and future financial trajectories. We detail regional dynamics, patent considerations, and emerging opportunities while providing quantitative data and strategic insights to assist stakeholders in informed decision-making.

---

Introduction

CYTOTEC (misoprostol) is a prostaglandin analog marketed by Pfizer, approved initially in 1980. Its versatility in gastrointestinal and obstetric indications has driven consistent demand. However, regulatory shifts, patent expirations, generics proliferation, and evolving healthcare policies are shaping its market trajectory.

---

Market Overview and Key Drivers

Aspect	Details
Global Market Size (2022)	Estimated at $750 million, with projections to reach $1.2 billion by 2030 (compound annual growth rate, CAGR, ~5.8%).
Major Regions	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa (EMEA).
Primary Application Areas	- Gastric ulcer prevention	- Medical abortion	- Labor induction	- Treatment of postpartum hemorrhage (PPH)
Key Growth Drivers	- Rising acceptance of medical abortion	- Expanding maternal healthcare programs	- Increasing prevalence of gastrointestinal disorders	- Projected legalization of abortion in previously restrictive regions (e.g., Latin America and parts of Asia)

Market Share Dynamics

Region	Market Share (2022)	Growth Drivers	Major Players (2022)
North America	40%	Regulatory approvals, high healthcare expenditure	Pfizer, Mylan, Teva
Europe	25%	Adoption in obstetrics, innovation in GI treatments	Pfizer, Sandoz, STADA
Asia-Pacific	20%	Large unmet needs, expanding healthcare access	Torrent Pharma, Sun Pharma, Pfizer (generic markets)
Latin America & Africa	15%	Increasing maternal health initiatives	Local and generic manufacturers

---

Regulatory Landscape and Patent Considerations

• Patent Status: Pfizer's original patents for CYTOTEC expired in most regions by the late 2010s, increasing generic competition.
• Regulatory Approvals: Approved in over 100 countries; regulatory pathways vary by region.
• Recent Trends:
  • Growing use as a combined medical abortifacient product globally.
  • Rigorous regulatory scrutiny around safety, dosage, and indications.

Regulatory Highlights	Implications
FDA approval for obstetric indications	Facilitates US-demand growth
European Medicines Agency (EMA) status	Ensures market access in Europe
Regional restrictions on use	Impact availability; potential for market segmentation

---

Competitive Environment and Market Players

Player	Market Share (Estimated, 2022)	Core Activities	Differentiators
Pfizer	~50%	Original patent holder, broad portfolio	Brand recognition, stability
Sandoz	~15%	Generic manufacturer	Price competitiveness
Teva	~10%	Generic drugs	Extensive distribution network
Local/Emerging Manufacturers	~25%	Regional brands	Cost advantages, tailored formulations

Emerging Competitors and Biosimilars

• Several Indian and Chinese firms are investing in low-cost generic manufacturing, intensifying price competition.
• Biosimilars and combination products are under development, targeting specific indications.

---

Financial Trajectory and Forecasts

Parameter	Current (2022)	Projected (2025)	Projected (2030)
Market Size	$750 million	~$950 million	$1.2 billion
Growth Rate (CAGR)	—	4.2% (2023-2025)	5.8% (2025-2030)
Key Revenue Contributors	North America, Europe	Asia-Pacific, Latin America	Global expansion

Revenue Breakdown by Region (2022)

Region	Revenue ($ million)	% of Total	CAGR (2023-2030)
North America	300	40%	4.0%
Europe	187.5	25%	3.8%
Asia-Pacific	150	20%	6.2%
Latin America & Africa	112.5	15%	6.4%

Cost Dynamics

• Manufacturing costs have declined due to increased generic manufacturing efficiencies.
• Regulatory compliance and safety monitoring constitute ongoing cost centers.

---

Key Market Opportunities

Expansion in Medical Abortion Market

• Legislative shifts in Latin America, including Argentina and Mexico, bolster demand.
• WHO recommends misoprostol as essential medicine for safe abortion, expanding outreach.

New Indications and Formulations

• Development of combined misoprostol formulations for labor induction.
• Novel delivery systems (e.g., controlled-release formulations).

Regional Market Penetration

Region	Potential for Growth	Strategic Focus
Asia-Pacific	High	Local manufacturing, partnerships
Latin America	High	Regulatory advocacy, local supply chains
Africa	Moderate	Health infrastructure integration

---

Risks and Challenges

Risk Factor	Impact	Mitigation Strategies
Regulatory restrictions	Reduced market access	Engage with regulators early, develop regional dossiers
Patent expirations	Increased competition	Accelerate lifecycle extension strategies
Safety concerns	Market bans or restrictions	Invest in pharmacovigilance, educate providers
Political and legislative changes	Impact on abortion applications	Monitor political shifts, diversify indications

---

Comparison with Similar Drugs and Market Benchmarks

Drug/Indication	Market Size (2022)	Primary Use	Key Competitors
Mifepristone + Misoprostol	$2.3B	Medical abortion (US, EU)	Danco Laboratories, HLL Lifecare
Dinoprostone	$600M	Labor induction	Ferring Pharmaceuticals
Lysteda (Tranexamic acid)	$300M	Menorrhagia	F. Hoffmann-La Roche

---

Strategic Insights for Stakeholders

• Manufacturers: Focus on regional regulatory navigation, cost-efficient generic production, and expanding indications.
• Investors: Target regions with legislative shifts favoring medical abortion and obstetric use.
• Healthcare Providers: Incorporate misoprostol into maternal health programs, balancing safety with accessibility.
• Policy Makers: Harmonize regulations to facilitate safe access while ensuring regulatory oversight.

---

Conclusion: Future Outlook

CYTOTEC's (misoprostol) global market is poised for modest but consistent growth driven by expanding indications, regulatory acceptance, and healthcare initiatives emphasizing maternal health. While patent expiries and generic competition challenge profitability, strategic focus on emerging markets, novel formulations, and integrated healthcare policies will shape its financial trajectory. Stakeholders must adapt to regional regulatory environments, safety considerations, and evolving treatment paradigms to maximize value.

---

Key Takeaways

• The global misoprostol market is projected to grow from $750 million in 2022 to $1.2 billion by 2030, with regional nuances shaping demand.
• Patent expiration has enabled increased generic competition, pressing downward pressure on prices but expanding access.
• Regulatory developments, especially in Latin America and Asia, are key drivers for future growth, particularly in medical abortion and maternal health.
• Emerging formulations and combination therapies present opportunities to extend lifecycle and capture new segments.
• Vertical integration, strategic regional partnerships, and compliance with safety standards are essential for sustainable market position.

---

FAQs

Q1: How does patent expiration impact CYTOTEC’s market?
Patent expiration has facilitated entry of numerous generics, increasing affordability and market penetration but exerting downward pressure on prices and profit margins for original manufacturers like Pfizer.

Q2: Which regions are forecasted to exhibit the highest growth?
Asia-Pacific and Latin America are expected to lead regional growth, driven by expanding healthcare access, regulatory changes favoring abortion safety, and local manufacturing.

Q3: What are the primary risks associated with misoprostol market expansion?
Regulatory restrictions, safety concerns, and political opposition to abortion services pose risks to market growth and product acceptance.

Q4: Are there new indications or formulations in development?
Yes, ongoing research explores combination formulations for labor induction, controlled-release systems, and expanding indications in postpartum hemorrhage management.

Q5: How do healthcare policies influence CYTOTEC’s commercial prospects?
Policies promoting maternal health and safe abortion access directly expand the market; conversely, restrictive legislation can impede growth opportunities.

---

References

[1] GlobalData, "Misoprostol Market Analysis," 2022.
[2] WHO, "Medical Management of Abortion," 2021.
[3] Pfizer, "CYTOTEC Product Monograph," 2022.
[4] European Medicines Agency, "Regulatory Status of Misoprostol," 2022.
[5] IMS Health, "Pharmaceutical Market Trends," 2022.